期刊文献+

多囊卵巢综合征患者子宫内膜不典型增生的药物转化分析 被引量:9

Drug Transformation Analysis of Endometrial Atypical Hyperplasia in Patients with Polycystic Ovary Syndrome(PCOS)
原文传递
导出
摘要 目的:分析多囊卵巢综合征(PCOS)患者子宫内膜不典型增生的药物转化疗效及安全性。方法:回顾性分析17例PCOS子宫内膜不典型增生患者,其中9例曾用孕激素治疗未转化者为A组;8例未曾治疗者为B组,均检测口服葡萄糖耐量试验(OGTT)并同时行胰岛素释放试验,以检测患者是否存在胰岛素抵抗(IR)及高胰岛素血症。17例患者均采用口服避孕药联合二甲双胍治疗。结果:17例PCOS患者均存在IR及高胰岛素血症,经药物治疗3-6个周期后,内膜不典型病变均成功转化。结论:采用口服避孕药联合二甲双胍治疗PCOS合并承的子宫内膜不典型增生患者是一种临床上实用、有效的治疗方法。 Objective: To analyze the efficacy and safety of drugs on reverse of atypical endometrial hyperplasia in patients with polycystic ovary syndrome (PCOS). Methods: A retrospective analysis on 17 patients with PCOS complicated by atypical endometrial hyperplasia was performed (9 patients who were treated with progestin but not reversed were considered as group A; 8 patients who were untreated were considered as group B). Both groups received OGTT and insulin release test, to check whether the patients had insulin resis- tance (IR) or hyperinsulinemia. The 17 patients were treated with oral contraceptives combined with metformin. Results: After the 17 patients with PCOS complicated by IR and hyperinsulinemia received drug treatment for 3-6 cycles, atypical endometrial 'hyperplasia was successfully reversed. Conclusion: Oral contraceptives combined with metformin is a clinically practical and effective method for treatment of PCOS complicated by atypical IR endometrial hyperplasia.
出处 《生殖与避孕》 CAS CSCD 2014年第1期36-40,共5页 Reproduction and Contraception
关键词 多囊卵巢综合征(PCOS) 子宫内膜不典型增生 胰岛素抵抗(IR) 口服避孕药(OC) 二甲双胍 polycystic ovary syndrome (PCOS) endometrial atypical hyperplasia insulin resistance (IR) oral contraceptive pills (OC) metformin
  • 相关文献

参考文献5

二级参考文献63

  • 1李昕,林金芳.肥胖型多囊卵巢综合征患者临床及内分泌代谢特征的研究[J].中华医学杂志,2005,85(46):3266-3271. 被引量:139
  • 2林金芳,李昕,朱铭伟.多囊卵巢综合征的分型探讨[J].中华妇产科杂志,2006,41(10):684-688. 被引量:74
  • 3Koo SH,FlechnerL, Qi L, et al. The CREB coactivator TORC2 isa key regulator of fasting glucose metabolism. Nature,2005,437: 1109-1111.
  • 4Mcgee SL, Hargreaves M. Exercise and skeletal muscle glucose transporter g expression: molecular mechanisms. Clin Exp Pharmacol Physio1,2006,33:395-399.
  • 5Hadad SM, Fleming S, Thompson AM. Targeting AMPK : a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol, 2008,67 : 1-7.
  • 6Evans JM, Donnelly LA, EmslieSmith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ, 2005,330: 1304-1305.
  • 7Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancerrelated mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care,2006,29:254-258.
  • 8Li DH, Yeung S J, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology,2009,137:482-488.
  • 9Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene,2008,27:3576-3586.
  • 10Isakovic A, Harhaji L, Stevanovic D, et al. Dual antiglioma action of metformin : cell cycle arrest and mitochondriadependent apoptosis. Cell Mol Life Sci,2007,64:1290-1302.

共引文献100

同被引文献118

引证文献9

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部